Ionis Pharmaceuticals Inc IONS
We take great care to ensure that the data presented and summarized in this overview for IONIS PHARMACEUTICALS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IONS
View all-
Vanguard Group Inc Valley Forge, PA16.5MShares$538 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD14.2MShares$463 Million0.31% of portfolio
-
Capital World Investors Los Angeles, CA11.5MShares$375 Million0.06% of portfolio
-
Black Rock Inc. New York, NY10.3MShares$337 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.67MShares$283 Million0.06% of portfolio
-
Bellevue Group Ag Kuesnacht, V87.87MShares$257 Million5.48% of portfolio
-
State Street Corp Boston, MA5.43MShares$177 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.83MShares$125 Million0.02% of portfolio
-
Tweedy Browne Co. Tweedy, Browne CO LLC | Stamford, Ct3.25MShares$106 Million7.97% of portfolio
-
Pictet Asset Management Sa Geneva 73, V83.1MShares$101 Million0.15% of portfolio
Latest Institutional Activity in IONS
Top Purchases
Top Sells
About IONS
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Insider Transactions at IONS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 04
2025
|
Brett P Monia Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
38,843
-17.69%
|
$1,204,133
$31.65 P/Share
|
|
Feb 04
2025
|
Patrick R. O'Neil EVP CLO & General Counsel |
SELL
Open market or private sale
|
Direct |
6,165
-9.69%
|
$191,115
$31.62 P/Share
|
|
Jan 31
2025
|
C Frank Bennett EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,327
-1.4%
|
$42,464
$32.46 P/Share
|
|
Jan 31
2025
|
Richard S Geary EVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,406
-1.4%
|
$44,992
$32.4 P/Share
|
|
Jan 31
2025
|
Elizabeth L Hougen EVP, Finance & CFO |
SELL
Open market or private sale
|
Direct |
1,523
-1.36%
|
$48,736
$32.44 P/Share
|
|
Jan 31
2025
|
Brett P Monia Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
13,242
-5.69%
|
$423,744
$32.45 P/Share
|
|
Jan 31
2025
|
Patrick R. O'Neil EVP CLO & General Counsel |
SELL
Open market or private sale
|
Direct |
1,406
-2.16%
|
$44,992
$32.49 P/Share
|
|
Jan 31
2025
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
SELL
Open market or private sale
|
Direct |
1,484
-2.37%
|
$47,488
$32.2 P/Share
|
|
Jan 31
2025
|
Eric Swayze EVP Research |
SELL
Open market or private sale
|
Direct |
1,367
-2.77%
|
$43,744
$32.31 P/Share
|
|
Jan 30
2025
|
C Frank Bennett EVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,607
+3.68%
|
-
|
|
Jan 30
2025
|
Richard S Geary EVP, Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,820
+3.66%
|
-
|
|
Jan 30
2025
|
Elizabeth L Hougen EVP, Finance & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
4,138
+3.56%
|
-
|
|
Jan 30
2025
|
Brett P Monia Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,372
+9.83%
|
-
|
|
Jan 30
2025
|
Patrick R. O'Neil EVP CLO & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
3,820
+5.55%
|
-
|
|
Jan 30
2025
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
BUY
Grant, award, or other acquisition
|
Direct |
4,032
+6.06%
|
-
|
|
Jan 30
2025
|
Eric Swayze EVP Research |
BUY
Grant, award, or other acquisition
|
Direct |
3,714
+6.99%
|
-
|
|
Jan 16
2025
|
Joseph Baroldi EVP, Chief Business Officer |
SELL
Open market or private sale
|
Indirect |
1,029
-25.1%
|
$32,928
$32.7 P/Share
|
|
Jan 16
2025
|
Joseph Baroldi EVP, Chief Business Officer |
SELL
Open market or private sale
|
Direct |
3,401
-11.97%
|
$108,832
$32.7 P/Share
|
|
Jan 16
2025
|
C Frank Bennett EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,752
-6.92%
|
$216,064
$32.9 P/Share
|
|
Jan 16
2025
|
Brian Birchler EVP, Corp and Development Ops |
SELL
Open market or private sale
|
Direct |
5,400
-8.93%
|
$172,800
$32.7 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 315K shares |
|---|---|
| Open market or private purchase | 5K shares |
| Grant, award, or other acquisition | 48.5K shares |
| Other acquisition or disposition | 3.33K shares |
| Open market or private sale | 223K shares |
|---|